--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-24-010557" form_type: "8-K" ticker: "BRKR" cik: "0001109354" company_name: "BRUKER CORP" filed_at: "2024-02-02T23:59:59+00:00" generated_at: "2026-06-06T09:44:08.523384+00:00" event_type: "debt" sentiment: "neutral" materiality_score: 0.5 calibrated_materiality_score: 0.5 confidence: "high" source: SEC EDGAR --- # Bruker Corp issues CHF 331M senior notes in three tranches at 2.56%-2.71%, due 2034-2039 ## Summary - CHF 50M Series A at 2.56% due 2034, CHF 146M Series B at 2.62% due 2036, CHF 135M Series C at 2.71% due 2039. - Closing expected on April 15, 2024; proceeds for acquisitions, refinancing, and general corporate purposes. - Unsecured notes guaranteed by certain subsidiaries; financial covenants: leverage ≤3.50x, interest coverage ≥2.50x, priority debt ≤15% of total assets. - Note purchase agreement entered February 1, 2024; private placement exempt from SEC registration. ## SEC filing metadata - accession: 0000950170-24-010557 - form_type: 8-K - ticker: BRKR - cik: 0001109354 - company_name: BRUKER CORP - filed_at: 2024-02-02T23:59:59+00:00 - event_type: debt - sentiment: neutral - materiality_score: 0.5 - calibrated_materiality_score: 0.5 - confidence: high - sec_items: 1.01, 2.03, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1109354/000095017024010557/0000950170-24-010557-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1109354/000095017024010557/brkr-20240202.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-24-010557 - JSON: https://secwatch.observer/filing/0000950170-24-010557.json - Plain text: https://secwatch.observer/filing/0000950170-24-010557.txt ## Key facts - Debt Financings BRUKER CORP incurred senior notes of CHF 146 million aggregate principal amount of its 2.62% Series B Senior Notes due April 15, 2036 at 2.62% maturing April 15, 2036. - Instrument: senior notes - Principal: CHF 146 million aggregate principal amount of its 2.62% Series B Senior Notes due April 15, 2036 - Rate: 2.62% - Maturity: April 15, 2036 - Event: incurrence source text: On February 1, 2024, the Bruker Corporation (the “Company”) entered into a note purchase agreement among the Company and the institutional accredited investors named therein (the “Note Purchase Agreement”), pursuant to which the Company will issue and sell (i) CHF 50 million aggregate principal amount of 2.56% Series A Senior Notes due April 15, 2034 (the “Series A Notes”), (ii) CHF 146 million aggregate principal amount of its 2.62% Series B Senior Notes due April 15, 2036 (the “Series B Notes”) and (iii) CHF 135 million aggregate principal amount of its 2.71% Series C Senior Notes due April 15, 2039 (the “Series C Notes” together with the Series A Notes and the Series B Notes, the “Notes”) in an offering exempt from the registration requirements of the Securities Act of 1933, as amended. evidence_url: https://www.sec.gov/Archives/edgar/data/1109354/000095017024010557/0000950170-24-010557-index.htm - Debt Financings BRUKER CORP incurred senior notes of CHF 50 million aggregate principal amount of 2.56% Series A Senior Notes due April 15, 2034 at 2.56% maturing April 15, 2034. - Instrument: senior notes - Principal: CHF 50 million aggregate principal amount of 2.56% Series A Senior Notes due April 15, 2034 - Rate: 2.56% - Maturity: April 15, 2034 - Event: incurrence source text: On February 1, 2024, the Bruker Corporation (the “Company”) entered into a note purchase agreement among the Company and the institutional accredited investors named therein (the “Note Purchase Agreement”), pursuant to which the Company will issue and sell (i) CHF 50 million aggregate principal amount of 2.56% Series A Senior Notes due April 15, 2034 (the “Series A Notes”), (ii) CHF 146 million aggregate principal amount of its 2.62% Series B Senior Notes due April 15, 2036 (the “Series B Notes”) and (iii) CHF 135 million aggregate principal amount of its 2.71% Series C Senior Notes due April 15, 2039 (the “Series C Notes” together with the Series A Notes and the Series B Notes, the “Notes”) in an offering exempt from the registration requirements of the Securities Act of 1933, as amended. evidence_url: https://www.sec.gov/Archives/edgar/data/1109354/000095017024010557/0000950170-24-010557-index.htm - Debt Financings BRUKER CORP incurred senior notes of CHF 135 million aggregate principal amount of its 2.71% Series C Senior Notes due April 15, 2039 at 2.71% maturing April 15, 2039. - Instrument: senior notes - Principal: CHF 135 million aggregate principal amount of its 2.71% Series C Senior Notes due April 15, 2039 - Rate: 2.71% - Maturity: April 15, 2039 - Event: incurrence source text: On February 1, 2024, the Bruker Corporation (the “Company”) entered into a note purchase agreement among the Company and the institutional accredited investors named therein (the “Note Purchase Agreement”), pursuant to which the Company will issue and sell (i) CHF 50 million aggregate principal amount of 2.56% Series A Senior Notes due April 15, 2034 (the “Series A Notes”), (ii) CHF 146 million aggregate principal amount of its 2.62% Series B Senior Notes due April 15, 2036 (the “Series B Notes”) and (iii) CHF 135 million aggregate principal amount of its 2.71% Series C Senior Notes due April 15, 2039 (the “Series C Notes” together with the Series A Notes and the Series B Notes, the “Notes”) in an offering exempt from the registration requirements of the Securities Act of 1933, as amended. evidence_url: https://www.sec.gov/Archives/edgar/data/1109354/000095017024010557/0000950170-24-010557-index.htm - Material Agreements BRUKER CORP entered into Note Purchase Agreement. - Action: entry - Agreement: notes offering source text: The foregoing summary description of the Note Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Note Purchase Agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference. evidence_url: https://www.sec.gov/Archives/edgar/data/1109354/000095017024010557/0000950170-24-010557-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.